C2N Diagnostics
Developing innovative diagnostics for Alzheimer's disease and related neurodegenerative conditions.
Launch date
Employees
Market cap
-
Enterprise valuation
€55—82m (Dealroom.co estimates Mar 2024.)
St. Louis Missouri (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | $20.0m | Grant | |
$2.2m | Grant | ||
* | $15.0m | Early VC | |
* | $15.0m | Early VC | |
| Total Funding | €47.5m | ||
Related Content
Recent News about C2N Diagnostics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.